Saltar al contenido

Opinion Summary: Hikma Pharmaceuticals v. Amarin Pharma | Generic Drug Beats Patent Trap

10 de junio de 2026 · 1 h 2 min

Notas del episodio

Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. | Case No. 24-889 | Docket Link: Here | Argued: 04/29/2026 | Decided: 06/04/2026

Overview: Amarin's cardiovascular drug patent faced challenge when generic maker Hikma launched a skinny-label version and marketed it through statements Amarin claimed encouraged doctors to prescribe the generic for the still-patented heart indication.

Question Presented: Whether a generic drug maker's marketing statements plausibly constitute "active steps" inducing patent infringement under 35 U.S.C. §271(b).

Posture: District Court dismissed; Federal Circuit reversed; Supreme Court reversed and remanded.

Main Arguments:

Petitioner (Hikma):

  • (1) Statements fully consistent with lawful skinny-label marketing cannot constitute active inducement under §271(b);
  • (2) Federal law mandated the label's contents, making legal compliance an obvious alternative explanation that forecloses liability;
  • (3) The Federal Circuit's physician-reading standard would destroy the Hatch-Waxman section viii pathway and expose generics to devastating litigation risk.

Respondent (Amarin):

  • (1) Hikma's totality of statements — repeatedly invoking "generic Vascepa," using an overbroad therapeutic category, and touting Vascepa's billion-dollar sales — plausibly encouraged infringing use;
  • (2) Amarin spent $300 million discovering the cardiovascular indication and patent law must protect that investment from free-riders;
  • (3) Seven other generic manufacturers avoided liability by accurately describing only their narrow approved uses, demonstrating Hikma's conduct fell outside normal practice.

Holding: Amarin failed to state a claim for active inducement in violation of §271(b); none of Hikma's alleged statements — individually or in totality — plausibly constituted active steps encouraging infringement of Amarin's cardiovascular-use patents.

Voting Breakdown: 9-0. Justice Jackson delivered the opinion for a unanimous Court. No Justice filed a separate opinion. Federal Circuit reversed and remanded.

Opinion: Here

Majority Reasoning:

  • (1) Active inducement requires affirmative steps to encourage infringement — not merely statements physicians could read as instructions to infringe;
  • (2) Hikma's label reflected legal compliance under the duty of sameness, its "generic Vascepa" description reflected standard industry practice, and omissions alone cannot support active inducement;
  • (3) Website category descriptions, patient leaflet warnings, and investor press release sales figures lacked the clear, affirmative message inducement demands.

Separate Opinions: None. The decision was unanimous.

Implications:

  • (1) Generic manufacturers may use the Hatch-Waxman skinny-label pathway without automatic inducement liability for routine commercial communications;
  • (2) Brand manufacturers must plead specific affirmative acts of encouragement — not inferences drawn from vague statements or omissions;
  • (3) The active inducement framework now applies with fresh clarity across all patent-holding industries.

The Fine Print:

  • 35 U.S.C. §271(b): "Whoever actively induces infringement of a patent shall be liable as an infringer."
  • 21 U.S.C. §355(j)(2)(A)(v): Requires a generic drug application to contain "information to show that the labeling proposed for the new drug is the same as the labeling approved for the [reference] listed drug . . . except for changes required because of differences approved under [applicable regulations]."

Primary Cases:

  • Metro-Goldwyn-Mayer Studios Inc. v. Grokster, Ltd. (2005): Active inducement requires purposeful, culpable expression and conduct designed to stimulate infringement; distributing a product capable of both infringing and non-infringing uses does not, alone, impose liability.
  • Bell Atlantic Corp. v. Twombly (2007): A complaint must plead facts supporting a plausible claim for relief; allegations carrying obvious alternative lawful explanations fail to clear the plausibility bar.

Oral Advocates:

  • Petitioners (Hikma): Charles B. Klein of Winston & Strawn LLP
  • Amicus Curiae (United States): Malcolm L. Stewart of the Department of Justice
  • Respondents (Amarin Pharma): Michael R. Huston of Perkins Coie LLP

Todos los episodios de The High Court Report

Ajustes

Visualización

Idioma

Determina qué emisoras ves primero en la página de inicio.

Historial

Las emisoras y episodios escuchados recientemente y tus últimas búsquedas solo se guardan en este navegador.

Avisos

Un breve aviso cuando un pódcast que sigues tiene un episodio nuevo. Puedes desactivar pódcast concretos con la campana de su página.

Cuenta

Guarda tus favoritos: en la app y en la web.

Atajos de teclado

/
Abrir búsqueda
Espacio
Reproducir o pausar
← →
En el reproductor: 15 s atrás, 30 s adelante (episodios) · en una fila: siguiente tarjeta
↑ ↓
En una fila: destino dentro de la tarjeta
Inicio / Fin
En una fila: primera o última tarjeta
Esc
Cerrar ventana o menú
?
Este resumen
Reproduciendo ahora

Ir a la emisora

A continuación

    Añade episodios con «A continuación»: sonarán después del episodio actual.